BrightPath Biotherapeutics Co Ltd (4594):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BrightPath Biotherapeutics Co Ltd (4594) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8082
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BrightPath Biotherapeutics Co Ltd (BrightPath Biotherapeutics), formerly GreenPeptide Co Ltd is a biopharmaceutical company that develops novel cancer immunotherapies. The company offers drug discovery research and early clinical development of cancer immunotherapy; early-phase clinical trials; and develops, manufactures, and launches the drugs as commercial products. BrightPath Biotherapeutics develops products for the diseases such as malignant brain tumor and advanced hormone refractory prostate cancer. The company offers immune related molecules to directly attack on cancer cells to prevent cancer relapse, metastasis and low slow cancer progression, among others. It operates in Kurume and Tokyo. BrightPath Biotherapeutics is headquartered in Kurume, Japan.

BrightPath Biotherapeutics Co Ltd (4594) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
GreenPeptide Raises USD11.6 Million in Venture Financing 10
Partnerships 11
GreenPeptide Enters into Research Agreement with Kanagawa Cancer Centre Research Institute 11
GreenPeptide Enters into Agreement with Bristol-Myers Squibb 12
Licensing Agreements 13
BrightPath Biotherapeutics Enters into Licensing Agreement with University of Tokyo 13
Acquisition 14
Green Peptide Plans to Acquire 67% Stake in Advanced Immunotherapy 14
BrightPath Biotherapeutics Co Ltd – Key Competitors 15
BrightPath Biotherapeutics Co Ltd – Key Employees 16
BrightPath Biotherapeutics Co Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Recent Developments 18
Other Significant Developments 18
May 12, 2017: GreenPeptide: Announcement on the Change of the Corporate Name and Partial Amendment to the Articles of Incorporation 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BrightPath Biotherapeutics Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
GreenPeptide Raises USD11.6 Million in Venture Financing 10
GreenPeptide Enters into Research Agreement with Kanagawa Cancer Centre Research Institute 11
GreenPeptide Enters into Agreement with Bristol-Myers Squibb 12
BrightPath Biotherapeutics Enters into Licensing Agreement with University of Tokyo 13
Green Peptide Plans to Acquire 67% Stake in Advanced Immunotherapy 14
BrightPath Biotherapeutics Co Ltd, Key Competitors 15
BrightPath Biotherapeutics Co Ltd, Key Employees 16
BrightPath Biotherapeutics Co Ltd, Other Locations 17

List of Figures
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BrightPath Biotherapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[BrightPath Biotherapeutics Co Ltd (4594):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tereos SA:企業の戦略的SWOT分析
    Tereos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Key Energy Services, Inc.:企業の戦略・SWOT・財務分析
    Key Energy Services, Inc. - Strategy, SWOT and Corporate Finance Report Summary Key Energy Services, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Royal DSM NV (DSM)-エネルギー分野:企業M&A・提携分析
    Summary Royal DSM NV (DSM) is a life sciences and materials sciences company, which focuses on health, nutrition and materials sectors. The company offers a wide range of products such as anti-invectives, polyesters, vitamins and other ingredients, performance materials to diverse end markets. It pr …
  • Living Cell Technologies Ltd (LCT):企業の財務・戦略的SWOT分析
    Living Cell Technologies Ltd (LCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Foundation Medicine Inc (FMI):企業の財務・戦略的SWOT分析
    Summary Foundation Medicine Inc (Foundation Medicine) is a molecular information products provider. The company provides molecular information and cancer research programs. It offers clinical products such as FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers, or hematolog …
  • Guess?, Inc.:戦略・SWOT・企業財務分析
    Guess?, Inc. - Strategy, SWOT and Corporate Finance Report Summary Guess?, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Eagle Pharmaceuticals Inc (EGRX):企業の財務・戦略的SWOT分析
    Eagle Pharmaceuticals Inc (EGRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Wallenstam AB (WALL B):企業の財務・戦略的SWOT分析
    Summary Wallenstam AB (Wallenstam) is a construction company that offers building and property management solutions. The company's services include commercial and residential properties development, housing programs, property investment and management, urban development, property ownership services, …
  • Encompass Health Corp (EHC):企業の財務・戦略的SWOT分析
    Encompass Health Corp (EHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Grupo Bimbo, S.A.B. de C.V. (BIMBOA):企業の財務・戦略的SWOT分析
    Grupo Bimbo, S.A.B. de C.V. (BIMBOA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ignyta Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ignyta Inc (Ignyta), formerly NexDx Inc, a subsidiary of F. Hoffmann-La Roche Ltd, is a cancer care service provider. The company discovers, develops and commercializes new drugs targeting activated genes in cancer cells. It develops products using integrated therapeutic technology (Rx/Dx). …
  • Sino Gas & Energy Holdings Ltd (SEH):石油・ガス:M&Aディール及び事業提携情報
    Summary Sino Gas & Energy Holdings Ltd (Sino Gas), a subsidiary of MIE Holdings Corp, is an oil and gas company that explores and develops unconventional gas assets production sharing contracts. The company holds working interest in the Linxing PSC and the Sanjiaobei PSC projects. It has strategic A …
  • Magnolia Petroleum Plc:石油・ガス:M&Aディール及び事業提携情報
    Summary Magnolia Petroleum Plc (Magnolia Petroleum) is an oil and gas company. The company explores, acquires, and develops oil and natural gas properties. It holds interests in producing properties in two project areas such as Bakken shale in North Dakota and the proven Mississippi Lime, Woodford a …
  • Baker Hughes, a GE Co LLC:企業の戦略的SWOT分析
    Baker Hughes, a GE Co LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Phatra Leasing Public Company Limited (PL):企業の財務・戦略的SWOT分析
    Phatra Leasing Public Company Limited (PL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • International Dairy Queen, Inc.:企業の戦略的SWOT分析
    International Dairy Queen, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Bioanalytical Systems Inc (BASI):企業の財務・戦略的SWOT分析
    Summary Bioanalytical Systems Inc (Bioanalytical Systems) is a contract research organization that provides drug discovery and development services, and analytical instruments. The company’s contract research services include screening and pharmacological testing, formulation development, preclinica …
  • ACHP Plc:企業の戦略・SWOT・財務情報
    ACHP Plc - Strategy, SWOT and Corporate Finance Report Summary ACHP Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Kuwait Food Company (Americana) KSCP:企業の戦略的SWOT分析
    Kuwait Food Company (Americana) KSCP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Diagnostica Stago Inc:企業の製品パイプライン分析2018
    Summary Diagnostica Stago Inc (Stago), a subsidiary of Diagnostica Stago SAS, is a medical device company that develops and distributes in-vitro diagnostic products. The company develops coagulation automation systems. It provides products such as hemostasis analyzers, viscosity based detection syst …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆